Differentiation of tryptic enzymes based on enantiomeric specificity at the deacylation step  by Yamada, Hiroyuki et al.
Volume 227, number 2, 195-197 FEB 05518 January 1988 
Differentiation of tryptic enzymes based on enantiomeric specificity 
at the deacylation step 
Hiroyuki Yamada, Kazutaka Tanizawa and Yuichi Kanaoka 
Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060, Japan 
Received 7December 1987 
The chiral specificity of tryptic enzymes at their deacylation step has been determined for the first time by virtue of ‘inverse 
substrates’ carrying optically active acyl groups. Differentiation of tryptic enzymes was also successful with these sub- 
strates. The stability of acyl-thrombin is substantially higher than those of trypsin and plasmin when the (S)-dihydro- 
coumarilyl group is applied. This is in contrast to the result with its (R)-antipode in which all three enzymes are not 
differentiated. The use of chiral p-amidinophenyl esters is proposed as a versatile methodology for the design of specific 
inhibitors capable of discriminating among tryptic enzymes. 
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1. INTRODUCTION 
Catalyses by thrombin and plasmin are directly 
related to physiological processes, such as coagula- 
tion and fibrinolysis, respectively. It is of great 
value for clinical purposes to design specific com- 
pounds which can distinguish between these en- 
zymes. The development of such compounds is 
difficult because these enzymes have similar 
substrate specificity. Inverse substrates, p- 
amidinophenyl esters, appear promising for this 
objective by virtue of their kinetic characteristics 
[l-3]. They react commonly with tryptic enzymes 
to produce a variety of acyl enzymes specifically, 
and the stabilities of the resultant acyl enzymes 
were expected to be diverse depending on the struc- 
ture of acyl groups and on the enzymes. Our in- 
terest is also focused on the response of tryptic 
enzymes toward chiral acyl groups at their deacyla- 
tion steps, which was not capable of being anal- 
yzed previously. 
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2. EXPERIMENTAL 
2.1. Materials 
Bovine trypsin was obtained from Worthington (lot TRL). 
Human plasmin and human thrombin were prepared as in [4,5]. 
Concentrations of enzyme preparations were determined on the 
basis of titrated normality [6] or reported rate constant [7]. Op- 
tically active inverse substrates, la-h, were prepared as 
reported [8]. 
2.2. Determination of kinetic parameters 
Hydrolyses of In-h by trypsin, thrombin and plasmin were 
determined in 0.05 M Tris-HCl (pH 8.0) at 25°C by monitoring 
the liberation of p-amidinophenol at 305 nm. The rapid acyla- 
tion process was analyzed by a stopped-flow spectrophotometer 
under either condition [S] * [E] ([S], 20-1OOpM; [El, 1 ,uM), 
or IS] 4 [El ([S], 0.5 PM; [El, 1.5-10 ,uM). A very slow deacyla- 
tion rate for the thrombin-catalyzed hydrolysis of (s)-Ic was 
determined from the reactivation of the isolated acyl enzyme. 
All the kinetic analyses were performed as reported [1,8]. 
3. RESULTS AND DISCUSSION 
Optically active inverse substrates, Ia-h, were 
synthesized from highly purified optically active 
carboxylic acid and N-carbobenzyloxy-p-amidino- 
phenol [8]. Their structures are shown in fig.1. 
Catalytic properties of bovine trypsin, human 
thrombin and human plasmin towards these 
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Fig. 1. Structure of optically active inverse substrates. 
substrates were analyzed. It was substantiated that 
all the esters were susceptible to the enzymatic 
catalyses in a specific manner. Every substrate was 
analyzed and shown to have a strong affinity to 
these three enzymes with a KS value ranging from 
10m5 to lo-’ M. The reactions proceeded through 
hibiting efficient acylation and slower deacylation 
steps as discussed in [8]. It was shown that the 
acylation rate constants, kz, were greater than the 
deacylation rate constants, k3, in every case, thus 
producing ratios k2/k3 which ranged from 1.4 to 
7970. Our interest is focused on the deacylation 
the formation of an acyl enzyme intermediate, ex- process which reflects the stability of the resultant 
Table 1 
Comparison of the deacylation rate constants 
Inverse 
substrate 
Trypsina 
kj ratio 
UW(S) 
Thrombin” 
k3 ratio 
(WG’l 
Plasminb Qplasmin)/ 
kj(thrombin) 
k3 ratio 
UW(s) 
(R)-la 
(S)-Ia 
(R)-Ib 
(Wb 
(R)-Ic 
(We 
(R)-Id 
W-Id 
(R)-le 
(We 
(R)-If 
(Wf 
(R)-Ig 
09-k 
(R)-IL 
(Wh 
5.5 x 10-l 
4.6 x 10-l 
1.2 
1.3 x 10-l 7.9 x 1o-2 1.6 
2.6 x 10’ 4 -l 56 
5.0 x 10’ 
1.2 x 10’ 
4l 
8.2 x lo+ 2.6 0.32 x lo-’ 
8.1 x lo-’ 2 10-z 3 . 9 
1.1 x 10-2 8.1 
x 
10-2 0.14 
1.1 x 10-l 
5.4 x 10-l 0.20 
3.0 x 10-l 
4.0 x 10-2 7.5 
1.1 x 10-2 
3.4 x 10-2 0.32 
5.4 1.3 x 1o-4 42000 
8.2 
5.2 1.6 
2.7 x 1O-4 
1.1 x 10-3 0.25 
3.3 x lo-* 
1.1 3.0 x lo-* 
6.8 x 1o-3 
2.5 x lo-* 2’7 
7.3 x 1o-3 
1.4 x 10-l 0.05 
1.1 x 10-l 
x 10-l 1 .o 
0.37 
1.0 2.5 
1.3 x 10-Z 1.2 
4.3 x 10-z 0.31 1.3 
1.0 x IO’ 1.9 
2.0 x 10-l 50 1500 
3.4 
1.0 
3.4 0.41 
0.19 
1.7 x 1o-3 
0.29 6.3 5.8 x lo-’ 5.3 
5.6 x lo-* 1.7 
1.9 x 10-2 
2.9 
1.7 
9.6 x lo-’ 1.4 
2.0 x 10-2 0.48 0.8 
1.0 x 10-2 
1.4 x 10-l 0.07 
1.4 
1.0 
a In 0.05 M Tris, 0.02 M CaC12 (pH 8.0) at 25°C 
b In 0.05 M Tris, 0.1 M NaCl, 0.02 M lysine (pH 8.0) at 25°C 
196 
Volume 227, number 2 FEBS LETTERS January 1988 
acyl enzymes. In table 1 deacylation rate constants 
for the 16 enantiomers in the catalysis by these 
three enzymes are listed. Enantiomers were 
classified on the basis of the sequence rule and 
denoted as R and S. The enantiomeric preferences 
proved to be variable for each case. For the com- 
pounds with an ether linkage (Ic,d,f) the 
preference is towards the R series. The greatest 
preference occurred in the thrombin-catalyzed 
reaction of Ic. In this case the R/S ratio is 4.2 x 
104, whereas the ratios for trypsin and plasmin are 
only 56 and 50, respectively. Compound (s)-Ic led 
to a remarkable discrimination between the tryptic 
enzymes. The deacylation rate decreased 
dramatically only in the case of the thrombin- 
catalyzed reaction, whereas (R)-Ic indicated little 
differentiation. We feel that this anomalous 
behavior of (9-1~ relative to thrombin catalysis 
can be explained on the basis of the spatial struc- 
tures of the tryptic enzymes and the orientation of 
the oxygen atom of the benzofuran ring. 
Molecular modeling [9] of acyl trypsin suggests 
that the oxygen atom of (R)-Ic is oriented toward 
His-57 in the active site whereas that of (s)-Ic is 
oriented toward Gln-192. It should be noted that a 
mutation of an amino acid residue occurred at 
position 192 of the thrombin molecule, i.e. Gln for 
trypsin and plasmin is replaced by Glu for throm- 
bin [IO,1 11. It is recognized that the instability 
ratio of acyl-plasmin to acyl-thrombin is 1500 for 
(s)-Ic, but only 1.9 for (R)-Ic. Apparently, (5’)-Ic 
inhibits thrombin activity by producing the long- 
lived acyl-thrombin (half-life 1.5 h), irrespective of 
the presence of plasmin. Plasmin activity has vir- 
tually no effect due to the short-lived nature of 
acyl-plasmin (half-life 3.5 s). Discrimination of en- 
zymes of similar specificity is possible by locating 
the amino acid mutation in the region near the ac- 
tive sites. Specific introduction of a chiral acyl 
group is feasible for sensitive differentiation of 
tryptic enzymes due to the temporary blocking of 
the enzyme activity. This approach will provide a 
new methodology for the development of clinically 
useful specific inhibitors of tryptic enzymes. 
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